President & Chief Executive Officer
Mark Timney joined Purdue Pharma L.P. as President and Chief Executive Officer in 2014, following an impressive career with Merck, where he served in leadership roles for 15 years within the United States and abroad. Before joining Purdue, Mr. Timney was President of Global Primary Care for Merck U.S. In this position his responsibilities included worldwide marketing for Primary Care, Women’s health and biologics businesses. Before assuming responsibility for Merck’s Global Primary Care organization, Mr. Timney was President of Merck & Co., U.S. Among his accomplishments during this time, he launched an important new hepatitis C treatment and led the acquisition and integration of a company that formed the basis of Merck Ophthalmics. Prior to the U.S., Mr. Timney served as President of Merck Japan, where he led the Schering-Plough Integration and three successful brand launches. Prior to that, Mr. Timney k was President of MSD Korea for more than four years and held leadership positions for another four years at Merck Australia. Before joining Merck, he spent eight years in commercial roles at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom.
Mr. Timney is a member of the Boards of both the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), has been featured in Life Science Leader magazine and was recognized by PharmaVOICE as one of 2015’s 100 Most Inspiring People. Mr. Timney earned a Bachelor’s degree in Sports Marketing at Newcastle Polytechnic, now Northumbria University, in Newcastle, England.